Flputnam Investment Management Co. Invests $586,000 in Regeneron Pharmaceuticals, Inc. $REGN

Flputnam Investment Management Co. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 939 shares of the biopharmaceutical company’s stock, valued at approximately $586,000.

Other hedge funds also recently made changes to their positions in the company. WPG Advisers LLC lifted its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $805.93 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11. The company’s 50-day moving average is $679.69 and its 200 day moving average is $714.24. The company has a market capitalization of $82.98 billion, a price-to-earnings ratio of 19.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $12.81 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock worth $1,090,030 in the last three months. Insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Canaccord Genuity Group lowered their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Truist Financial lifted their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $801.70.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.